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ABSTRACT
This study aimed to show, based on the literature on the subject, the potential 
for dispersal and establishment of the chikungunya virus in Brazil. The 
chikungunya virus, a Togaviridae member of the genus Alphavirus, reached 
the Americas in 2013 and, the following year, more than a million cases 
were reported. In Brazil, indigenous transmission was registered in Amapa 
and Bahia States, even during the period of low rainfall, exposing the whole 
country to the risk of virus spreading. Brazil is historically infested by Ae. 
aegypti and Ae. albopictus, also dengue vectors. Chikungunya may spread, 
and it is important to take measures to prevent the virus from becoming 
endemic in the country. Adequate care for patients with chikungunya 
fever requires training general practitioners, rheumatologists, nurses, and 
experts in laboratory diagnosis. Up to November 2014, more than 1,000 
cases of the virus were reported in Brazil. There is a need for experimental 
studies in animal models to understand the dynamics of infection and the 
pathogenesis as well as to identify pathophysiological mechanisms that 
may contribute to identifying effective drugs against the virus. Clinical 
trials are needed to identify the causal relationship between the virus and 
serious injuries observed in different organs and joints. In the absence of 
vaccines or effective drugs against the virus, currently the only way to 
prevent the disease is vector control, which will also reduce the number of 
cases of dengue fever.
DESCRIPTORS: Chikungunya Virus. Alphavirus Infections, epidemiology. 
Disease Outbreaks. Risk Factors. Epidemiological Surveillance. 
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Chikungunya virus (CHIKV) was first isolated from 
human serum during a febrile illness outbreak in 
Tanzania in 1953.24 The word chikungunya is derived 
from Makonde (Kimakonde), one of the languages 
spoken in southeastern Tanzania, and means “to bend 
over or become contorted”, referring to the posture 
adopted by the patient due to serious joint pain in severe 
infections caused by CHIKV.11,23 The virus is a member 
of the family Togaviridae, genus Alphavirus, antigenic 
complex Semliki forest, also composed by alphavi-
ruses Ross River, O’nyong-nyong, Getah, Bebaru, 
Semliki forest, and Mayaro, the latter being endemic 
in the Brazilian Amazon. It has four genetically distinct 
strains: West African, East-Central-South African 
(ECSA), Asian and Indian Ocean lineage (IOL).19,32
The disease caused by CHIKV, known as chikungunya 
fever, is clinically characterized by fever, headache, 
myalgia, exanthema, and arthralgia – the most 
pronounced symptoms, which may persist for months 
or years in some patients and sometimes evolve into 
disabling chronic arthropathy.7,28
Several combined factors have contributed to the emer-
gence and spread of arboviruses such as CHIKV and 
dengue in new areas, including the global distribution of 
their potential vectors: Ae. aegypti and Ae. albopictus.
Since the isolation in Tanzania, CHIKV has been asso-
ciated with disease in Africa and Asia. However, since 
2005 the virus has quickly spread in the islands of the 
southwestern Indian Ocean. Many imported cases were 
observed in non-Western countries, as Italy, where a 
CHIKV outbreak occurred in 2007. The cases have 
continued to occur and, in 2013, CHIKV was intro-
duced in the Caribbean region, expanding in 2014 for 
the continental areas of the Americas.16
In Brazil, Ae. aegypti is disseminated in all states and 
widely dispersed in urban areas, while Ae. albopictus 
is found in several municipalities, except for the states 
of Sergipe, Acre, Amapa and Roraima. In addition, the 
total susceptibility of the Brazilian population to CHIKV, 
combined with other factors, such as the detection of 
imported cases in travelers since 2010,1,6 suggests poten-
tial dispersal and establishment of CHIKV throughout the 
country. The objective of this study was to show, based 
on the literature on the subject, the potential for dispersal 
and establishment of the CHIKV in Brazil.
Emergence of CHIKV in new areas
The spread of CHIKV in humans is usually supported 
by the urban cycle (human-mosquito-human). 
However, wild cycles keep the virus in wild environ-
ments, as already evidenced in Africa and Asia, with 
sporadic human cases.9,12,13
INTRODUCTION 
There are records of CHIKV epidemics since 1779, 
however mistakenly registered as dengue outbreaks.5 
Between 1960 and 1990, the virus was isolated on 
several occasions during numerous outbreaks in coun-
tries of Central and Southern Africa (Sudan, Uganda, 
the Democratic Republic of the Congo, Malawi, 
Zimbabwe, Kenya and South Africa), as well as in 
countries of West Africa, including Senegal, Benin, 
Guinea, Ivory Coast, and Nigeria. The occurrence of 
outbreaks or evidence of chikungunya fever in Africa is 
generally associated with rainy periods, followed by a 
virus spillover from a wild enzootic cycle to an epizo-
otic cycle, usually urban. Outbreaks in rural areas can 
occur when the vector density increases in areas with 
non-immune populations.
Since the 1960s, frequent outbreaks have also been 
reported in Southeast Asian countries such as India, 
Malaysia, Indonesia, Cambodia, Vietnam, Myanmar, 
Pakistan, and Thailand.20 In 1999-2000, CHIKV 
caused an epidemic in Kinshasa, capital of Democratic 
Republic of Congo, after 39 years without any isola-
tion of the virus. Between 2001 and 2003, the virus 
resurfaced in Indonesia after an absence of 20 years.10,18
Until 2004, the cases of chikungunya fever were 
restricted to African and Asian countries. However, in 
April 2005, CHIKV was detected in the South-West 
Indian Ocean (Comoros Islands), probably intro-
duced by viremic travelers from Lamu (Kenya), 
where an outbreak was registered in June 2004.25 The 
virus quickly dispersed throughout the Indian Ocean 
islands (Comoros, Madagascar, Mayotte, Seychelles, 
Mauritius, Réunion), resulting in an epidemic in 2005 
and 2006. During this period, clinical observations 
of cases with atypical presentations (neurological 
involvement, disease in newborns and deaths) and the 
transmission by Ae. albopictus in Réunion led to the 
hypothesis that a new genotype, possibly more viru-
lent, was associated with the cases. The epidemic in 
Réunion (2005-2006) was associated with the IOL 
genotype of CHIKV, identified as a descendant of 
ECSA, which contains adaptive mutations in the 
envelope protein genes (E1 and E2). These mutations 
enabled the increase in CHIKV infectivity for Ae. 
Albopictus, a highly competent vector that allowed the 
efficient replication and dispersion of CHIKV during 
the outbreak.30-32 During this period, the ECSA geno-
type was introduced in Asia.29 In fact, about 13 states 
in India have registered cases of the disease after a 
32-year interepidemic period; outbreaks have also 
occurred in Malaysia, Sri Lanka, and Indonesia.29 In 
addition, imported cases have been confirmed in trav-
elers returning from endemic regions of Asia and Indian 
Ocean islands to countries in Asia (Hong Kong, Japan, 
Singapore, Sri Lanka and Taiwan), Europe (Germany, 
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Belgium, Spain, France, Italy, Norway, Czech Republic, 
Switzerland and Ukraine), North America (USA and 
Canada), and Oceania (Australia).a
In 2007, a new outbreak occurred in India, with 
Ae. aegypti as the vector, and in Northern Italy 
(Emilia-Romagna), with indigenous cases of chikun-
gunya fever transmitted by Ae. albopictus. Outbreaks 
continued to occur in countries in Asia and also in India. 
In 2009 and 2010, after some years of latency, CHIKV 
reemerged in Réunion. Furthermore, imported cases 
were detected in several countries of the Americas, 
including Brazil with three travelers who returned from 
Indonesia and India in 2010.1,6
Concerns about the spread and establishment of 
the virus in the Americas and other countries grew 
primarily from 2011, when an outbreak with more than 
11,000 cases occurred in the Democratic Republic of 
the Congo. Indeed, in 2013 a dissemination of cases 
occurred, with indigenous transmission of the disease 
in several countries of the Caribbean (French Guiana, 
Saint Martin, Martinique, Guadeloupe, Dominican 
Republic, St. Barths and the British Virgin Islands) 
and in January 2014 the first cases were detected in the 
mainland of Central America. Imported cases, some 
of them viremic, have appeared in Brazil since June 
2014. In September of that year, the first case with 
indigenous transmission was detected in the country, 
in the state of Amapa. In that same month, a CHIKV 
outbreak was detected in Feira de Santana, BA. The 
Brazilian Ministry of Health reported that, in 2015, until 
the epidemiological week 15 (from January 4, 2015 
to April 18, 2015), 3,135 suspected cases (indigenous 
transmission) of chikungunya fever were reported in 
the states of Amapa and Bahia, of which 1,688 were 
confirmed, five by laboratory criteria and 1,683 by 
clinical-epidemiological criteria.14
Still, many cases imported from the states of Amapa 
and Bahia as well as other countries were identified in 
several Brazilian states.14
We highlight that the circulating CHIKV genotype in 
Amapa is the Asian one, as in the Caribbean, while in 
Bahia it is the East-South-Central African one.15,26 The 
Figure shows the world distribution of CHIKV trans-
mission areas.
Clinical manifestations
Since the first description of the disease in the 1950s, 
the clinical recognition of fever and infection with 
CHIKV has relied on the reporting of epidemics in 
South Africa in the 1970s. These reports identified, 
after a short incubation period of two to six days (the 
mean is 12 days), the three-stage evolution of the 
disease with an acute phase of sudden onset of symp-
toms such as high fever, exanthema, and arthralgia, 
which affects mainly the small and large joints and can 
evolve into a subacute phase with resurgence of arthral-
gias. A third stage occurred in some cases that evolved 
into the chronic form of the disease with persistent 
polyarthralgia, which may be disabling for weeks or 
years.25 The classic clinical picture has been described 
in up to 95.0% of the patients of recent outbreaks and 
epidemics, while between 3.0% and 5.0% of infections 
are asymptomatic.28
Several clinical characteristics may be observed in 
patients with chikungunya fever. The reproductive 
capacity of the virus in different tissues, from the tegu-
ment to the central nervous system, cardiac muscle, 
joints, liver, among others, results in a wide variety of 
clinical manifestations.26
The skin changes described in the acute stage of the 
disease are present in 40.0% to 50.0% of cases. One 
of them is rash, usually maculopapular and pruritic, 
affecting mainly the chest, but also observed on the face 
and upper and lower limbs.2,4 The vesico-bullous type 
may also occur, with peeling of the extremities, most 
noted in children, as well as facial edema, ulcers of oral 
mucosa and vasculitis lesions as petechiae and gingival 
hemorrhage.2 Although spontaneous or induced bleeding 
(positive tourniquet test) may be present in chikungunya 
fever, large hemorrhages are not commonly described, 
which partially distinguishes it from severe forms of 
dengue, a disease in which the most severe hemorrhagic 
phenomena are frequent findings.22
Beside the typical clinical picture of chikungunya fever, 
clinical manifestations considered atypical have been 
frequently reported in the course of outbreaks and 
epidemics, including neurological, cardiac, renal and 
ocular changes, with higher incidence in people aged 
over 65 years and with preexisting conditions, which 
can result in complications and death. Nevertheless, 
most cases take the benign course of infection. The 
clinical spectrum of neurological complications is 
similar in adults and children and includes myeloneu-
ropathy, encephalitis, Guillain-Barre Syndrome, flaccid 
paralysis, and neuropathies. As for the ocular manifes-
tations, iridocyclitis and retinitis are the most frequent 
ones, with resolution and preservation of vision in most 
cases after six to eight weeks. Among cardiac changes, 
myocarditis, pericarditis, and dilated cardiomyopathy 
have been described. However, clinical and experi-
mental studies are needed to elucidate the effects of 
the virus in the cardiac muscle, as well as studying the 
relationship between cardiology changes in the course 
of chikungunya fever with history of heart disease.22
a Aldighieri S. Global response to emerging and re-emerging diseases [power point presentation]. In: PAHO Pre-Conference: Growing Global: 
Policy and Research Directions for Building Nursing Capacity; 2012 October 11; Washington, DC.
4 Chikungunya risk in Brazil Azevedo RSS et al
The impact of CHIKV infection in pregnancy has been 
widely studied, with evidence of high risk for first 
trimester abortion and last trimester maternal-fetal trans-
mission. In a classic study conducted by Gérardin et al8 
on this type of transmission, 7,504 CHIKV-infected 
pregnant women with laboratory confirmation (sero-
logical, virological, or both) were evaluated during the 
2006 outbreak, with three fetal deaths before the 22nd 
week of pregnancy reported. Vertical transmission was 
reported in 19 (31.0%) neonates from mothers who were 
viremic (n = 61) at the time of birth. The study also 
reported severe infection in 10 cases, nine of encepha-
lopathy and one of hemorrhagic fever.8
Chronic cases
Polyarthralgia is the classical articular manifesta-
tion of the disease soon after the onset of fever, of 
serious intensity and migratory nature, rare in children, 
symmetrically affecting large and small joints (hands, 
feet, phalanges and ankles), with limitation of motion. 
Patients generally report clinical improvement in artic-
ulations seven to 10 days after the onset of symptoms, 
except for joint stiffness and pain, which can persist 
for months or years in 12.0% of patients.21 This chronic 
stage of arthralgia is characterized by fluctuations in 
intensity of pain and relapse, usually affecting the same 
articulation as the acute stage, causing reduction in the 
range of motion and quality of life.3 Age is suggested as 
a risk factor associated with the persistence of arthralgia 
and destructive arthritis, as well as with the detection 
of IgM class antibodies up to two years after infection. 
The persistence of IgM detection is seen the most in 
infants and people aged over 45 years, in the presence 
of comorbidities and in cases of patients with greater 
intensity of joint pain in the acute stage of the disease.2,3 
It is postulated that infections by arthritogenic virus 
such as CHIKV may exacerbate preexisting collagen 
diseases, especially rheumatoid arthritis and osteoar-
thritis, but follow-up studies on patients with arbovi-
rosis are required to establish this causal relationship.2,3
Clinical and therapeutic approach
In the absence of effective drugs against CHIKV, clin-
ical management is based on symptomatic therapeutic 
regimens for the various stages of the disease. In the 
acute stage of the disease, the recommendations are rest, 
water intake, and use of antipyretics (acetaminophen, 
dipyrone). Nonhormonal anti-inflammatories (COX-2 
inhibitors) should be prescribed in the subacute stage. 
In the chronic stage, the use of corticosteroids (pred-
nisolone) and immunosuppressants (methotrexate) is 
recommended. The differential diagnosis with other 
infectious diseases and collagen diseases is imperative 
before starting any therapeutic regimen for patients.
Studies have observed that broad-spectrum antiviral 
drugs such as ribavirin and interferon are promising 
and that their combination shows synergistic effect 
on virus inhibition.2,17 However, additional studies 
are needed, including multidrug regimens, to assess 
cost-effectiveness and long-term side effects. Clinical 
studies involving the use of specific polyclonal immu-
noglobulin and human monoclonal antibodies have 
been arousing interest.4,21
Prevention is achieved by vector control and personal 
protection measures. The explosive character of the 
epidemics associated with the absence of a specific 
drug point to vaccination as the best effective strategy 
Figure. Areas with chikungunya virus transmission in the world.
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to protect the population at risk. Studies on vaccine 
candidates against CHIKV began in 1967, but so far 
no effective and licensed vaccine was developed. 
Preclinical studies with vaccine candidates tested in 
animals have been described. Some of the formula-
tions tested are inactivated, live attenuated, chimeric, 
recombinant DNA, peptide, protein subunit, recom-
binant adenovirus and virus-like particle (VLP) 
vaccines.17 Preliminary results of phase II clinical 
trials with a live attenuated vaccine (181/25 Asian 
genotype) were promising, inducing a robust neutral-
izing antibody response in 98.0% of vaccinated people 
and providing protection against the other genotypes 
(Central/African). However, the studies were discon-
tinued in 2000.21
Future prospects and challenges
The probable and imminent spread of CHIKV in 
the American continent should result in explosive 
epidemics as previously observed in Africa, Asia, 
and the Indian Ocean region. From November 2013 
(when the first indigenous cases in the Caribbean 
arised) to December 29, 2014, 1,071,696 suspected 
cases of chikungunya fever were reported to the 
Pan American Health Organization, mostly in the 
Caribbean, with laboratory confirmation of 22,796 
cases of indigenous transmission and 2,511 imported 
cases.16 The virus is expected to spread in Colombia, 
Venezuela, Brazil, and other South American coun-
tries in the summer of 2015. This possibility is due 
to the presence of two vectors of CHIKV, Ae. aegypti 
and Ae. albopictus, whose rates of infestation increase 
with summer rains. In addition, there already are 
chikungunya fever outbreaks in two Brazilian states 
(Amapa and Bahia), with indigenous transmission 
even during a low rainfall period. Therefore, the chal-
lenges are preventing the transmission in other states, 
controlling the spread of the disease in the states 
with established transmission, and decreasing vector 
infestation indices throughout the national territory, 
which, besides preventing indigenous circulation of 
CHIKV, would also result in a drastic reduction in 
the number of dengue cases. Another important chal-
lenge is to accelerate phase II and III clinical trials of 
vaccine candidates, which should be prioritized both 
in areas with established transmission and in receptive 
areas without indigenous transmission. Finally, clin-
ical trials to investigate the pathogenesis of chikun-
gunya fever in humans and experimental studies in 
nonhuman primates should constitute priorities for 
assessing the CHIKV potential of causing serious 
injury in vital organs and also in joints, where the pres-
ence of the virus in resident cells has been described.
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